Organization | SocraTec R&D GmbH

SocraTec R&D GmbH Report issue

For profit Phase 1 Phase 3 Phase 4

Founded: Frankfurt Germany (1998)

Status: No NME R&D (1998)

Organization Overview

First Clinical Trial

2009

NCT00884442

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

SocraTec R&D GmbH | SocraTec R&D GmbH Clinical Pharmacology Unit | SocraTec R&D GmbH, Clinical Pharmacology Unit

Active Ingredients

Drugs in Phase 4 Trials (1)

yohimbine (1 trial)

Drugs in Phase 3 Trials (2)

cetylpyridinium chloride (1 trial)

lidocaine (xylocaine) (1 trial)

Drugs in Phase 1 Trials (12)

cannabidiol (Epidiolex) (1 trial)

deferiprone (ferriprox) (1 trial)

esflurbiprofen (2 trials)

esomeprazole (nexium) (1 trial)

estriol (2 trials)

flurbiprofen (ansaid) (1 trial)

furosemide (lasix) (1 trial)

ibuprofen (motrin) (1 trial)

metronidazole (flagyl) (1 trial)

nifedipine (procardia) (1 trial)

rivastigmine (exelon) (4 trials)

trimegestone (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Common Cold (Phase 3)

Edema (Phase 1)

Erectile Dysfunction (Phase 4)

Pharyngitis (Phase 3)

Respiratory Tract Infections (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 17
# of Trial APIs: 15